title: The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985).
abstract: A number of studies have identified race as a prognostic factor for survival from prostate cancer. To evaluate the prognostic significance of race in a controlled setting, we evaluated 1294 patients treated on three prospective randomized trials conducted by the Radiation Therapy Oncology Group between 1976 to 1985. One-hundred and twenty (9%) of the patients were coded as black, while 1077 (83%) of the patients were coded as white. Protocol 7506 included 607 patients with clinical Stage T3-T4Nx or T1b-T2N1-2. Protocol 7706 included 484 patients with clinical Stage T1b or T2 who were node negative. Protocol 8307 included 203 Stage T2b-T4 patients with no lymph node involvement beyond the pelvis. Univariate and multivariate analyses were used to assess the possible independent significance of race and other prognostic factors, including Gleason score, serum acid phosphatase, nodal status, and hormonal status. Protocols 7706 and 8307 revealed that race was not of prognostic significance for disease-free or overall survival by either univariate or multivariate analysis. Univariate analysis of Protocol 7506 revealed that the median survival for blacks was somewhat shorter (5.4 years vs. 7.1 years, p = 0.02). This difference persisted after a multivariate analysis. A higher percentage of blacks treated on 7506 had an abnormally elevated serum acid phosphatase compared to whites (p = 0.006), and the time to distant failure tended to be shorter (p = 0.07). These findings suggest that blacks treated on 7506 may have had more extensive disease at presentation. Based on these prospective randomized trials, it is most likely that the lower survival noted for black Americans with prostate cancer reflects the tendency for blacks to present with more advanced disease. Differences in access to care, the quality of care received, and the impact of co-morbid conditions may explain the lower survival reported for black Americans elsewhere in the literature.
authors.affiliation: Department of Radiation Oncology, University of California, San Francisco 94143-0226.
authors.forename: M
authors.initials: M
authors.lastname: Roach
authors.forename: J
authors.initials: J
authors.lastname: Krall
authors.forename: J W
authors.initials: JW
authors.lastname: Keller
authors.forename: C A
authors.initials: CA
authors.lastname: Perez
authors.forename: W T
authors.initials: WT
authors.lastname: Sause
authors.forename: R L
authors.initials: RL
authors.lastname: Doggett
authors.forename: M
authors.initials: M
authors.lastname: Rotman
authors.forename: H
authors.initials: H
authors.lastname: Russ
authors.forename: M V
authors.initials: MV
authors.lastname: Pilepich
authors.forename: S O
authors.initials: SO
authors.lastname: Asbell
mesh_terms: D001741:Black or African American; D000368:Aged; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D011379:Prognosis; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000208:ethnology* / Q000401:mortality / Q000532:radiotherapy*; D012044:Regression Analysis; D016019:Survival Analysis; D015996:Survival Rate; D014481:United States / Q000208:ethnology